Cefazolin-induced coagulopathy: a case report

头孢唑林诱发的凝血功能障碍:病例报告

阅读:2

Abstract

OBJECTIVE: We report a case of cefazolin-induced coagulopathy, highlighting the importance of maintaining a high index of suspicion for this rare adverse effect of cefazolin. SETTING: Department of intensive care, Rabin Medical Center, Hasharon Hospital, Petach Tikvah, Israel. PATIENT: A patient presented with shortness of breath, pleural effusion, iatrogenic pneumothorax, and bacteremia (positive for coagulase-negative staphylococcus). INTERVENTIONS: Multiple thoracic drains and high-dose cefazolin therapy (2 gr intravenously three times per day). CASE REPORT: A 78-year-old Caucasian woman with a history of mild renal dysfunction, chronic obstructive pulmonary disease, and morbid obesity was admitted to the Emergency Medicine Ward with new-onset shortness of breath. Initial evaluation revealed pleural effusion and positive blood cultures for Staphylococcus lugdunensis. Consequently, high-dose intravenous cefazolin (2 gr three times per day) was initiated. The patient's clinical condition deteriorated, necessitating mechanical ventilation and continuous renal replacement therapy in the intensive care unit. Management included echocardiography, placement of three pleural drains to address pneumothoraces, and intravenous antibiotic therapy. On the fourth day of cefazolin treatment, the patient experienced a significant rise in international normalized ratio (inr = 20 at day 4) levels, reaching 15-20, despite the absence of overt bleeding. After ruling-out primary hematologic disorders, cefazolin-induced coagulopathy was suspected. Cefazolin was discontinued, and vitamin K supplementation was promptly administered. This intervention led to a rapid normalization of international normalized ratio levels. CONCLUSION: Cefazolin-induced coagulopathy is a potentially life-threatening complication that may present with or without overt bleeding a few days after initiating intravenous cefazolin therapy. Owing to its rarity, this adverse effect requires heightened awareness and familiarity with predisposing risk factors to ensure timely recognition and management.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。